Emtricitabine
- TRADE NAMES: Atripla (Gilead); Complera (Gilead); Descovy (Gilead); Emtriva (Gilead); Truvada (Gilead)
- INDICATIONS: HIV-1 infection
- CLASS: Antiretroviral, Nucleoside analog reverse transcriptase inhibitor
- HALF-LIFE: ~10 hours
Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Ganciclovir, Lamivudine, Ribavirin, Valganciclovir
PREGNANCY CATEGORY: B
Emtricitabine is a fluorinated derivative of lamivudine.
Atripla is emtricitabine, efavirenz and tenofovir disoproxil; Complera is emtricitabine, rilpivirine and tenofovir disoproxil; Descovy is emtricitabine and tenofovir alafenamide; Truvada is emtricitabine and tenofovir disoproxil.
See also separate profiles for emtricitabine in combination with cobicistat, elvitegravir and tenofovir disoproxil or tenofovir alafenamide.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of emtricitabine with tenofovir disoproxil in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/02/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
